GNPX Genprex, Inc.
Company Updates ·
A poster from the company's Meharry Medical College collaboration is scheduled for the Gerontological Society of America meeting in National Harbor, Maryland, in November 2026.
A peer-reviewed mouse study tied the TUSC2 gene, used in Genprex's REQORSA program, to protein balance and synaptic function in the hippocampus.
The contract manufacturer will make drug product for IND-enabling preclinical studies and future clinical trials of the company's AAV-based diabetes gene therapy.
Nasdaq's Hearings Panel confirmed on August 4, 2026 that Genprex regained the $1.00 minimum bid price, but the panel keeps jurisdiction until December 7, 2026.
The panel's July 29, 2026 decision lets Genprex stay listed on the Nasdaq Capital Market while it keeps a closing bid of at least $1.00 each trading day until December 7, 2026.
The split, approved by the board on July 2, 2026, moves shares outstanding from 11,108,577 to approximately 504,936, and the company released an investor presentation the same day.
The Canadian Intellectual Property Office issued a notice of allowance for a patent covering REQORSA with PD-1 or PD-L1 antibodies in lung cancer.
A June 10, 2026 Nasdaq letter said Genprex would be delisted unless it requested a hearing, because its stock closed under $1.00 for 30 consecutive business days and it had a reverse split on October 21, 2025.
A Genprex-supported abstract at the 2026 ASCO Annual Meeting linked Trop-2 and PTEN protein levels to progression-free survival in non-small cell lung cancer, but not in small cell lung cancer.
Research collaborators presented data showing the company's Pdx1 and MafA gene therapy reversed hyperglycemia in a type 2 diabetes mouse model at the 2026 ASGCT Annual Meeting in Boston.
Nasdaq says Genprex's equity of $1,391,195 is below the $2.5 million minimum, adding a second basis for delisting to an unresolved bid price failure. A hearing request has stayed any delisting for now.
Stockholders' equity of $1,391,195 at June 30, 2025 is below the $2.5 million minimum. Genprex has asked for a Nasdaq Hearings Panel hearing, which pauses any delisting while the process runs.
The company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | |
| Research and development | $9.4 million | $10.5 million |
| Net income (loss) | -$16.2 million | -$21.1 million |
| Cash from operations | -$15.3 million | -$17.9 million |
| Cash and equivalents | $7.8 million | $1.6 million |
Our latest story on this, dated Jul 14, 2026: "Genprex plans a 1-for-22 reverse stock split effective July 16". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 12, 2026: "Nasdaq staff says Genprex is not eligible for a bid price compliance period". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 18, 2025: "Genprex gets second Nasdaq deficiency notice, with equity at $1,391,195". The story links the filing or release it is based on. Read the story.
Genprex, Inc. trades under the ticker GNPX on NASDAQ.
Genprex, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A8I.
The SEC Central Index Key (CIK) for Genprex, Inc. is 1595248. Its filings are on SEC EDGAR.
819,709 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Genprex, Inc. under United States.
Our directory classifies Genprex, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Genprex, Inc. is US3724464017.
aibio.space lists Genprex, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as TX.
Genprex, Inc. reported a net loss of $16.2 million for the fiscal year ended Dec 31, 2025, and used $15.3 million of cash in operations, per its annual report to the SEC.
$9.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$15.2 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio